Development of new tuberculosis drugs: translation to regimen composition for drug-sensitive and multidrug-resistant tuberculosis

JP Ernest, N Strydom, Q Wang, N Zhang… - Annual review of …, 2021 - annualreviews.org
Tuberculosis (TB) kills more people than any other infectious disease. Challenges for
developing better treatments include the complex pathology due to within-host immune …

Global sensitivity analysis of biological multiscale models

M Renardy, C Hult, S Evans, JJ Linderman… - Current opinion in …, 2019 - Elsevier
Mathematical models of biological systems need to both reflect and manage the inherent
complexities of biological phenomena. Through their versatility and ability to capture …

Cumulative human health risk analysis of trihalomethanes exposure in drinking water systems

M Kumari, SK Gupta - Journal of Environmental Management, 2022 - Elsevier
Chlorinated compounds on reaction with natural organic substances present in water leads
to the formation of trihalomethanes (THMs), a major type of disinfection by-products (DBPs) …

[HTML][HTML] Both pharmacokinetic variability and granuloma heterogeneity impact the ability of the first-line antibiotics to sterilize tuberculosis granulomas

JM Cicchese, V Dartois, DE Kirschner… - Frontiers in …, 2020 - frontiersin.org
Tuberculosis (TB) remains as one of the world's deadliest infectious diseases despite the
use of standardized antibiotic therapies. Recommended therapy for drug-susceptible TB is …

[HTML][HTML] A computational model tracks whole-lung Mycobacterium tuberculosis infection and predicts factors that inhibit dissemination

T Wessler, LR Joslyn, HJ Borish… - PLoS computational …, 2020 - journals.plos.org
Mycobacterium tuberculosis (Mtb), the causative infectious agent of tuberculosis (TB), kills
more individuals per year than any other infectious agent. Granulomas, the hallmark of Mtb …

[HTML][HTML] A multi-scale pipeline linking drug transcriptomics with pharmacokinetics predicts in vivo interactions of tuberculosis drugs

JM Cicchese, A Sambarey, D Kirschner… - Scientific Reports, 2021 - nature.com
Tuberculosis (TB) is the deadliest infectious disease worldwide. The design of new
treatments for TB is hindered by the large number of candidate drugs, drug combinations …

[HTML][HTML] A Credibility Assessment Plan for an In Silico Model that Predicts the Dose–Response Relationship of New Tuberculosis Treatments

C Curreli, V Di Salvatore, G Russo… - Annals of Biomedical …, 2023 - Springer
Tuberculosis is one of the leading causes of death in several developing countries and a
public health emergency of international concern. In Silico Trials can be used to support …

[HTML][HTML] Mathematical models of drug-resistant tuberculosis lack bacterial heterogeneity: A systematic review

NM Fuller, CF McQuaid, MJ Harker… - Plos …, 2024 - journals.plos.org
Drug-resistant tuberculosis (DR-TB) threatens progress in the control of TB. Mathematical
models are increasingly being used to guide public health decisions on managing both …

Pulmonary delivery of linezolid nanoparticles for treatment of tuberculosis: design, development, and optimization

S Shah, H Maheshwari, M Soniwala… - Journal of Pharmaceutical …, 2022 - Springer
Purpose The present study was aimed to develop and optimize linezolid loaded chitosan
nanoparticles for pulmonary delivery. The objective was to achieve the mean particle size of …

A systematic efficacy analysis of tuberculosis treatment with BPaL‐containing regimens using a multiscale modeling approach

M Budak, LE Via, DM Weiner… - CPT …, 2024 - Wiley Online Library
Tuberculosis (TB) is a life‐threatening infectious disease. The standard treatment is up to
90% effective; however, it requires the administration of four antibiotics (isoniazid, rifampicin …